AI
Friday, March 02, 2012 10:02:02 PM
If you could somehow combine the X from Baxter it would really be great 
!
On one of their recent presentations they sounded really bullish on its prospects but there are a few caveats:
1-They wont push product immediately (I think in part because of capacity). They said about needing to properly train people too.
2-They will only be going after certain indications in the immunoglobulin market (I didn't catch witch but I think total its ~1.5B) and one figures some won't switch to sub-q.
I imagine they will try to expand label/use over time but don't see it as a more gradual build rather than a huge immediate switch of patients. Of course if their Alzheimers trials do well the immunoglobulin market becomes enormous.
! On one of their recent presentations they sounded really bullish on its prospects but there are a few caveats:
1-They wont push product immediately (I think in part because of capacity). They said about needing to properly train people too.
2-They will only be going after certain indications in the immunoglobulin market (I didn't catch witch but I think total its ~1.5B) and one figures some won't switch to sub-q.
I imagine they will try to expand label/use over time but don't see it as a more gradual build rather than a huge immediate switch of patients. Of course if their Alzheimers trials do well the immunoglobulin market becomes enormous
. Trade Smarter with Thousands
Leverage decades of market experience shared openly.
